ClinicalTrials.gg
WithdrawnNCT07534813Updated Jun 9, 2026

A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors

An interventional study of GT307 injection in Advanced Solid Tumors, sponsored by Grit Biotechnology. Withdrawn at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Grit Biotechnology · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Due to procedural adjustments at the investigative site, domestic registration on the China health authority's platform must be finalized prior to re-submission on ClinicalTrials.gov. Therefore, we hereby withdraw the current submission.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study adopts a single-center, single-arm, open-label design. It aims to evaluate the safety and tolerability of GT307 in patients with advanced solid tumors, as well as assess its pharmacokinetic profile and efficacy, and determine the optimal dosage regimen.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Grit Biotechnology is the lead sponsor of 30 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntarily participate in the study, sign the form, and be willing and able to comply with the study protocol.
  • 2. Age between 18 and 70 years (cases over 70 years of age shall be jointly determined by the investigator and the sponsor's medical monitor).
  • 3. Recurrent or solid tumors that have failed systemic therapy, including but not limited to cervical cancer, malignant melanoma, non-small cell lung cancer, and head and neck cancer.
  • 4. At least one lesion that has not received radiotherapy or other local therapies and from which tumor tissue can be obtained (as judged by the investigator), and the resected lesion can yield a tissue mass of ≥1.0 cm³ (from a single lesion or combined from multiple lesions) for the preparation of autologous tumor-infiltrating lymphocytes; minimally invasive procedures shall be used whenever possible.
  • 5. After tumor sampling, at least one as defined by v1.1 is present, which has not received radiotherapy or other local therapies (unless such therapy was administered more than 3 months prior and the lesion has demonstrated progression).
  • 6. (ECOG) performance status score of 0 or 1.
  • 7. Expected survival time ≥ 12 weeks.
  • 8. Function of vital organs meets the following requirements:

    1. Routine blood tests: reference ranges are provided below, and final judgment may be made by the investigator considering variations in normal reference ranges across central laboratories:

      • (ANC) ≥ 1.0 × 10⁹/L;
      • Lymphocyte count (LC) ≥ 0.5 × 10⁹/L;
      • count (PLT) ≥ 80 × 10⁹/L;
      • (Hb) ≥ 90 g/L.
    2. Liver function tests: (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ; total (TBIL) ≤ 1.5 × ULN. Criteria may be relaxed under the following conditions:

      • Confirmed liver metastasis: AST and/or ALT ≤ 5 × ULN;
      • Confirmed liver or bone metastasis: ALP ≤ 5 × ULN;
      • Confirmed Gilbert syndrome: total bilirubin (TBIL) ≤ 3.0 mg/dL.
    3. Renal function tests: (CrCL) ≥ 45 mL/min (calculated using the Cockcroft-Gault formula), or serum creatinine (Cr) within normal range; and urine protein (Pro) \< 2+.
    4. Coagulation function tests: ≤ 1.5 × ULN, and international normalized ratio (INR) or PT ≤ 1.5 × ULN.
    5. Good cardiac function.
    6. Good pulmonary function.
  • 9. Women of who are not surgically sterilized must agree to use at least one medically accepted method (e.g., intrauterine device, oral contraceptives, or condoms) during study treatment and for 1 year after the end of study treatment. Female participants of childbearing potential who are not surgically sterilized must have a negative serum human chorionic gonadotropin (HCG) test within 7 days prior to cell infusion.
  • 10. Adverse events resulting from prior therapy have resolved ( 5.0 ≤ Grade 1) before tumor sampling, or are judged by the investigator and the sponsor's physician to have no impact on this study.
  • 11. Participants enrolled due to disease progression must have radiographic documentation of disease progression following the most recent prior therapy before tumor sampling.

Exclusion criteria

Exclusion Criteria:

  • 1. Patients with spinal cord compression that has not been relieved by surgery and/or radiotherapy shall not be enrolled (treated patients may be enrolled if clinical evidence shows symptom relief for ≥ 1 week prior to surgical sampling).
  • 2. Patients with uncontrolled tumor-related pain as judged by the investigator. Participants requiring analgesic therapy must have a stable analgesic regimen at study entry; symptomatic lesions eligible for palliative radiotherapy should have completed treatment prior to study entry.
  • 3. Bleeding events occurring within 3 months prior to screening, including but not limited to gastrointestinal bleeding due to gastric fundal or esophageal varices, increased bleeding risk due to portal hypertension, active gastrointestinal bleeding, etc.; or patients assessed by the investigator to be at high risk of major bleeding, including but not limited to tumor encasement or invasion of major blood vessels (i.e., carotid artery, jugular vein, bronchial artery) and/or other high-risk features such as fistula, significant cavitary lesions, history of hemorrhage (≤ 60 days from signing ICF).
  • 4. Active arterial/venous thrombotic events occurring within 3 months prior to screening, including but not limited to cerebrovascular accident, deep vein thrombosis, pulmonary embolism, etc.
  • 5. Presence of respiratory diseases severely affecting pulmonary function.
  • 6. History of cardiovascular diseases, including but not limited to:

    1. Congestive heart failure ( [NYHA] class > 2);
    2. Unstable angina;
    3. Myocardial infarction within the past 3 months;
    4. Any supraventricular or ventricular arrhythmia requiring treatment or intervention.
  • 7. Participants with ≥ 3 untreated central nervous system (CNS) at screening (participants with ≤ 3 , maximum diameter \< 1 cm, no peritumoral edema on brain imaging [MRI or CT], and no evidence of progressive CNS disease on brain imaging for at least 3 months after treatment may be enrolled).
  • 8. History of disease, or active autoimmune disease requiring systemic or therapy (> 10 mg/day prednisone or equivalent).
  • 9. Presence of or intractable epilepsy, uncontrolled massive pleural effusion, ascites, pericardial effusion, etc., active gastrointestinal bleeding, or to IL 2 administration.
  • 10. other than the target indication diagnosed within 5 years prior to screening (excluding adequately treated basal cell or squamous cell skin cancer, radically resected ductal carcinoma in situ of the breast, etc.), unless the investigator determines that the benefits to the participant outweigh the risks.
  • 11. Presence of infectious diseases at screening, such as , syphilis, active hepatitis, active pulmonary tuberculosis, active EBV and/or CMV infection.

Patients positive for surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) may participate if HBV DNA is below the lower limit of normal (LLN) of the local laboratory.

Patients positive for anti- antibody may participate if HCV RNA is below the LLN of the local laboratory.

Carriers shall receive antiviral therapy as appropriate and undergo regular quantitative nucleic acid testing during the study.

  • 12. Patients with prior bone marrow transplantation or solid organ transplantation.
  • 13. Administration of anti-angiogenic agents such as VEGF/bevacizumab within 4 weeks prior to tumor sampling.
  • 14. Receipt of systemic anti-tumor therapy within 4 weeks prior to lymphodepletion conditioning, except for the following:

    • Bridging therapy;
    • For prior nitrosourea or mitomycin C chemotherapy, at least 6 weeks must elapse between the end of chemotherapy and the planned first study drug administration;
    • For prior small-molecule targeted therapy, at least 5 half-lives of the agent must elapse between the end of treatment and the planned first study drug administration.
  • 15. Prior receipt of genetically modified or edited cell therapy products (excluding unmodified/unedited autologous immune cell therapy products administered more than 1 year before cell infusion).
  • 16. History of to any component of the study agents (including but not limited to autologous tumor-infiltrating lymphocytes, cyclophosphamide, fludarabine, interleukin 2, dimethyl sulfoxide [DMSO], human serum albumin [HSA], dextran 40, antibiotics [β lactams, gentamicin]).
  • 17. Known psychiatric disorders, alcoholism, drug addiction or substance abuse.
  • 18. Prior immune-related adverse events of Grade 3 or higher that did not resolve to Grade 1 or lower within 28 days; any disease or condition (any other medical disorder, metabolic dysfunction, physical examination finding or laboratory abnormality) that would reasonably contraindicate the use of the product, interfere with interpretation of study results, or place the participant at high risk of treatment complications.
  • 19. Pregnant or lactating women, or women planning to become pregnant, lactate or conceive within 1 year after cell infusion.
  • 20. Receipt of other investigational clinical trial drugs within 4 weeks prior to screening, or planning to participate in other investigational clinical trials during the study period.
  • 21. Any other conditions deemed inappropriate for enrollment by the investigator.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    GT307 injection treatment group

    Biological: GT307 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of the safety of GT307 in the treatment of advanced solid tumors

    Adverse events shall be reported and graded in accordance with CTCAE Version 5.0. All adverse events (AEs) occurring from the signing of the informed consent form up to 24 weeks after GT307 infusion shall be collected.

    Time frame: 24 months

  2. Evaluation of the tolerability of GT307 in the treatment of advanced solid tumors

    Adverse events shall be reported and graded in accordance with CTCAE Version 5.0. All adverse events (AEs) occurring from the signing of the informed consent form up to 24 weeks after GT307 infusion shall be collected. All concomitant medications used from 28 days prior to signing the informed consent form up to 24 weeks after cell infusion shall be documented.

    Time frame: 24 months

Secondary outcomes

  1. overall response rate (ORR)

    The proportion of patients whose tumor size reduces to the predefined criteria (complete response + partial response) and maintains for the specified duration, reflecting the short-term anti-tumor activity of a drug.

    Time frame: 24 months

  2. Progression-Free Survival(PFS)

    The time from randomization or initiation of treatment to the first documentation of disease progression or death from any cause.

    Time frame: 24 months

  3. To monitor the pharmacokinetics of GT307 Injection in the treatment of advanced solid tumors.

    PK blood samples will be collected from participants for pharmacokinetic monitoring of GT307 Injection via blood testing at the following time points: prior to the start of lymphodepletion conditioning therapy (on the day of initiation), prior to GT307 Injection infusion (Day -1), and on Days 3, 5, 7, 10, 14, 21 ± 3, 28 (Week 4) ± 3, 42 (Week 6) ± 3, 63 (Week 9) ± 7, 84 (Week 12) ± 7, 126 (Week 18) ± 7, 168 (Week 24) ± 7 post-infusion, as well as at follow-up visits every 3 months thereafter. PK blood sampling may be discontinued if TIL are undetectable in peripheral blood on two consecutive occasions.

    Time frame: 24 months

07

Study locations

1 site
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai Municipality 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for May 2028, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 16, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07534813
Lead sponsor
Grit Biotechnology
Collaborators
Fudan University
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Jun 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Tumor-infiltrating Lymphocytes GT307

Start the discussion